We are live on ! Find out more

1,145 hedge funds and large institutions have $62.8B invested in Biogen in 2018 Q3 according to their latest regulatory filings, with 142 funds opening new positions, 345 increasing their positions, 467 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more first-time investments, than exits

New positions opened: 142 | Existing positions closed: 84

21% more capital invested

Capital invested by funds: $51.9B → $62.8B (+$10.9B)

4% more funds holding

Funds holding: 1,0971,145 (+48)

3.35% more ownership

Funds ownership: 84.82%88.17% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 2828 (0)

26% less repeat investments, than reductions

Existing positions increased: 345 | Existing positions reduced: 467

41% less call options, than puts

Call options by funds: $1.11B | Put options by funds: $1.88B

Holders
1,145
Holders Change
+48
Holders Change %
+4.38%
% of All Funds
26.18%
Holding in Top 10
28
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.64%
New
142
Increased
345
Reduced
467
Closed
84
Calls
$1.11B
Puts
$1.88B
Net Calls
-$775M
Net Calls Change
-$249M
Name Holding Trade Value Shares
Change
Change in
Stake
Arrowstreet Capital
26
Arrowstreet Capital
Massachusetts
$505M -$130M -376,925 -21%
Franklin Resources
27
Franklin Resources
California
$407M +$1.25M +3,642 +0.3%
Wells Fargo
28
Wells Fargo
California
$355M -$14.6M -42,527 -4%
Morgan Stanley
29
Morgan Stanley
New York
$345M -$267M -774,604 -44%
TCIM
30
TIAA CREF Investment Management
New York
$344M -$25.6M -74,333 -7%
Legal & General Group
31
Legal & General Group
United Kingdom
$336M -$7.66M -22,260 -2%
VOYA Investment Management
32
VOYA Investment Management
Georgia
$332M +$284M +826,232 +732%
O
33
OrbiMed
New York
$322M -$88.7M -257,600 -22%
DZ Bank
34
DZ Bank
Germany
$314M +$20.6M +59,889 +7%
Charles Schwab
35
Charles Schwab
California
$314M -$11.2M -32,534 -4%
O
36
OppenheimerFunds
New York
$305M -$28.4M -82,558 -9%
Renaissance Technologies
37
Renaissance Technologies
New York
$299M +$181M +524,575 +163%
Macquarie Group
38
Macquarie Group
Australia
$284M +$23.9M +69,498 +9%
LSV Asset Management
39
LSV Asset Management
Illinois
$268M +$57.9M +168,183 +28%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$258M -$22.5M -65,415 -8%
PAMU
41
Pictet Asset Management (UK)
United Kingdom
$245M -$38.7M -112,534 -14%
Sumitomo Mitsui Trust Group
42
Sumitomo Mitsui Trust Group
Japan
$240M +$4.54M +13,192 +2%
Swiss National Bank
43
Swiss National Bank
Switzerland
$238M -$8.95M -26,000 -4%
PPA
44
Parametric Portfolio Associates
Washington
$230M -$25.1M -73,037 -10%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$223M -$359K -1,043 -0.2%
JIM
46
Jupiter Investment Management
United Kingdom
$219M +$213M +619,105 New
Lazard Asset Management
47
Lazard Asset Management
New York
$208M -$33.8M -98,256 -14%
TA
48
Teachers Advisors
New York
$201M +$14.3M +41,637 +8%
Allianz Asset Management
49
Allianz Asset Management
Germany
$199M -$46.9M -136,332 -19%
APG Asset Management
50
APG Asset Management
Netherlands
$193M +$6.03M +17,500 +3%

BIIB Hedge Fund Activity: Q3 2018 in Review

1,145 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2018, worth a combined $62.8B — up 21% from $51.9B a quarter earlier.

Buyers outnumbered sellers: 142 funds opened new BIIB positions and 84 closed out — a net gain of 58 holders — while 345 added to existing stakes and 467 trimmed.

The largest buyer was Capital World Investors, adding an estimated $710M. The largest seller was Janus Henderson Group, cutting an estimated $372M.

  • 1,145 institutional investors held Biogen (BIIB) as of Q3 2018, up from 1,097 in Q2 2018.
  • Funds reported $62.8B of Biogen stock for Q3 2018, up 21% quarter-over-quarter.
  • 142 funds opened new Biogen positions in Q3 2018 and 84 closed out, a net change of +58 holders.
  • The largest Biogen buyer in Q3 2018 was Capital World Investors, an estimated $710M added.
  • The largest Biogen seller in Q3 2018 was Janus Henderson Group, an estimated $372M sold.

Based on aggregated 13F filings for Q3 2018.